Astellas Pharma (OTCMKTS:ALPMY) Stock Price Crosses Below 50 Day Moving Average – Should You Sell?

Astellas Pharma Inc. (OTCMKTS:ALPMY)’s share price crossed below its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $13.76 and traded as low as $13.1850. Astellas Pharma shares last traded at $13.25, with a volume of 134,199 shares trading hands.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on ALPMY. Jefferies Financial Group raised shares of Astellas Pharma from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, March 24th. Zacks Research upgraded shares of Astellas Pharma from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, June 23rd. Two analysts have rated the stock with a Strong Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, Astellas Pharma currently has a consensus rating of “Moderate Buy”.

Astellas Pharma Price Performance

The company has a fifty day simple moving average of $13.76 and a two-hundred day simple moving average of $14.64. The stock has a market capitalization of $23.98 billion, a price-to-earnings ratio of 12.34 and a beta of 0.07. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.84 and a current ratio of 1.09.

Astellas Pharma (OTCMKTS:ALPMY) last released its earnings results on Monday, April 27th. The company reported $0.33 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.19 by $0.14. Astellas Pharma had a return on equity of 24.19% and a net margin of 13.66%.The company had revenue of $3.38 billion for the quarter, compared to analyst estimates of $3.28 billion. As a group, equities research analysts expect that Astellas Pharma Inc. will post 1.25 earnings per share for the current fiscal year.

About Astellas Pharma

Astellas Pharma Inc is a Tokyo-based, global pharmaceutical company traded in the United States as an American Depositary Receipt on the OTC Markets under the symbol ALPMY. The company focuses on discovering, developing and marketing prescription medicines in key therapeutic areas, including oncology, urology, immunology, neuroscience and cardiovascular/metabolic diseases. Astellas seeks to bring innovative treatments to market by combining internal research capabilities with external partnerships and collaborative agreements around the world.

Core products in Astellas’ portfolio include the immunosuppressant Prograf (tacrolimus), the overactive bladder treatments Vesicare (solifenacin) and Myrbetriq (mirabegron), and the prostate cancer therapy Xtandi (enzalutamide).